Navellier & Associates Inc Neurocrine Biosciences Inc Transaction History

Navellier & Associates Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 16, 2019	SELL	$83.82 - $101.5 $1.74 Million - $2.11 Million	-20,760 Closed	0 $0
Q2 2019 Jul 17, 2019	SELL	$72.24 - $91.27 $288 - $365	-4 Reduced 0.02%	20,760 $1.75 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $52,467 - $69,288	757 Added 3.78%	20,764 $1.83 Million
Q4 2018 Jan 15, 2019	SELL	$68.32 - $124.36 $777,959 - $1.42 Million	-11,387 Reduced 36.27%	20,007 $1.43 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $3.1 Million - $3.95 Million	31,394 New	31,394 $3.86 Million

650

96.2M

380K

382K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.